Dutch Statutory Board Report And Financial Statements

Overview

The report presents 2023 consolidated revenue of EUR 53,758 thousand and a year-end workforce of 1,126 employees. It describes continued Phase 2 COVID-19 and seasonal influenza vaccine programs and a Phase 1 CVGBM oncology study. The report also says CureVac initiated an ESG-related project in 2023, while its sustainability objectives assessment was not yet formalized.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023
Period: Ends 31 December 2023
Publication date: 24 April 2024
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services